


Presently Pending Claims

Language to be added has been **bolded and underlined>**, while language to be deleted has been **bolded-and-striken-through**.


1-20. (Canceled)

21. (Currently amended) A compound represented by the structural formula I



or a pharmaceutically acceptable salt ~~or solvate~~ thereof; wherein:

R¹ is



R² is selected from the group consisting of H, alkyl, aryl, arylalkyl, heteroarylalkyl, alkylketone, arylketone, alkyl, haloalkyl, cycloalkyl, cycloalkylalkyl, alkylsulfonyl, arylsulfonyl, alkoxyalkyl, or amide;

R³ is selected from the group consisting of 6-membered heteroaryl, and 6-membered heteroaryl-N-oxide, wherein said 6-membered heteroaryl or heteroaryl-N-oxide is a pyrimidine or a pyrimidine-N-oxide respectively, each of which is optionally substituted with 1-4 substituents which can be the same or different and are independently selected from the group consisting of R¹¹, R¹², R¹³, R¹⁴ and R¹⁵,

R⁴ is 1-3 -(C₁-C₆)alkyl-N(R²¹)SO₂R²², wherein R⁴ can be the same or different and is independently selected when there is more than one R⁴ present;

R⁹, R¹⁰ and B can be the same or different and are each independently selected from the group consisting of hydrogen, (C₁-C₆)alkyl, and -(C₁-C₆)haloalkyl;

R¹¹ and R¹² can be the same or different and are each independently selected from the group consisting of (C₁-C₆)alkyl, -(C₁-C₆)haloalkyl, halogen, -NR¹⁹R²⁰, -OH, CF₃, -OCH₃, -O-acyl, and -OCF₃;

R¹³ is selected from the group consisting of hydrogen, R¹¹, H, phenyl, -NO₂, -CN, -CH₂F, -CHF₂, -CHO, -CH=NOR¹⁹, pyridyl-N-oxide, pyrimidinyl, pyrazinyl, N(R²⁰)CONR²⁰R²¹, -NHCONH(chloro-(C₁-C₆)alkyl), -NHCONH((C₃-C₁₀)-cycloalkyl(C₁-C₆)alkyl), -NHCO(C₁-C₆)alkyl, -NHCOCF₃, -NHCOCF₃, -NHSO₂N((C₁-C₆)alkyl)₂, -NHSO₂(C₁-C₆)alkyl, -N(SO₂CF₃)₂, -NHCO₂(C₁-C₆)alkyl, (C₃-C₁₀)cycloalkyl, -SR²², -SOR²², -SO₂R²², -SO₂NH(C₁-C₆)alkyl, -OSO₂(C₁-C₆)alkyl, -OSO₂CF₃, hydroxy(C₁-C₆)alkyl, -CONR¹⁹R²⁰, -CON(CH₂CH₂-O-CH₃)₂, -OCONH(C₁-C₆)alkyl, -CO₂R₁₉, -Si(CH₃)₃ and -B(OC(CH₃)₂)₂;

R¹⁴ is selected from the group consisting of (C₁-C₆)alkyl, -(C₁-C₆)haloalkyl -NH₂ and R¹⁵-phenyl;

R¹⁵ is 1-3 substituents selected from the group consisting of hydrogen, (C₁-C₆)alkyl, -(C₁-C₆)haloalkyl, -CF₃, -CO₂R²⁰, -CN, (C₁-C₆)alkoxy and halogen; wherein R¹⁵ can be the same or different and is independently selected when there are more than one R¹⁵ present;

R¹⁹, R²⁰ and R²¹ can each be the same or different and are each independently selected from the group consisting of H, (C₁-C₆)alkyl and (C₃-C₆)cycloalkyl;

R²² is selected from the group consisting of (C₁-C₆)alkyl, -(C₁-C₆)haloalkyl, (C₂-C₆)hydroxyalkyl, (C₂-C₆)alkylene, (C₃-C₆)cycloalkyl, aryl and aryl(C₁-C₆)alkyl-;

A is selected from the group consisting of H, (C₁-C₆)alkyl, and (C₂-C₆) alkenyl.







M is aryl optionally substituted with R⁴, wherein said aryl is phenyl; and

Q is CH or N, with the following proviso:

when R¹ is phenyl, R² cannot be H, -(C₁-C₆)alkyl or -C(O)-(C₁-C₆)alkyl.

22. (Currently amended) A compound having the structural formula I, or a pharmaceutically acceptable salt thereof, according to claim 21 wherein




R^9 , R^{10} and B are H, A is $-CH_3$, and R^1 , R^2 and R^3 are as defined in the following table:

#	R ¹	R ²	R ³
47			
48			
56			
57			

23. (Previously presented) A compound according to claim 22 wherein R¹, R² and R³ each represent:

#	R ¹	R ²	R ³
47			
56			
57			

24. (Currently amended) A compound according to claim 23 represented by the structural formulae:



or a pharmaceutically acceptable salt thereof.

25. (Currently amended) A pharmaceutical composition comprising a therapeutically effective amount of one or more compounds of claim 21, or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable carriers.

26. (Currently amended) A pharmaceutical composition comprising a therapeutically effective amount of one or more compounds of claim 24, or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable carriers.

27-40. (Canceled)